

AD-A106 055

LETTERMAN ARMY INST OF RESEARCH PRESIDIO OF SAN FRANC--ETC F/6 6/20  
THE MUTAGENIC POTENTIAL OF: 4-FLUOROPHENYL METHYL (PHENYL) PHOS--ETC(U)  
SEP 81 L J SAUERS, F R PULLIAM, J T FRUIN

UNCLASSIFIED

LAIR-106

NL

I or I  
A106 055

END  
DATE FILMED  
11-81  
RTIC

AD A106055

LEVEL 1

(12)

INSTITUTE NO. 106

THE MUTAGENIC POTENTIAL OF:

4-fluorophenyl methyl (phenyl) phosphinate,  
4-nitrophenyl 4-trifluoromethylphenyl (methyl) phosphinate,  
4-nitrophenyl 3-trifluoromethylphenyl (methyl) phosphinate,  
4-methylsulfinylphenyl methyl (phenyl) phosphinate

DTIC FILE COPY.

LEONARD J. SAUERS / BA, SP5  
FREDDICA R. PULLIAM / BS, SSG  
JOHN T. FRUIN / DVM, PhD, LTC VC

DTIC  
SELECTED  
OCT 23 1981

E


TOXICOLOGY GROUP,  
DIVISION OF RESEARCH SUPPORT

This document has been approved  
for public release and sale; its  
distribution is unlimited.

11 SEP 1981

(12) 36

Toxicology Series - 19



LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO CALIFORNIA 94129

Toxicology Series 19

Reproduction of this document in whole or in part is prohibited except with the permission of the Commander, Letterman Army Institute of Research, Presidio of San Francisco, California 94129. However, the Defense Technical Information Center is authorized to reproduce the document for United States Government purposes.

Destroy this report when it is no longer needed. Do not return it to the originator.

Citation of trade names in this report does not constitute an official endorsement or approval of the use of such items.

This material has been reviewed by Letterman Army Institute of Research and there is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author(s) and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. (AR 360-5)

*Joyce L. Marshall 9/8/87 p.1*  
(Signature and date)

## UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER  LAIR Institute Report No. 106	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) The Mutagenic Potential of 4 fluorophenyl methyl(phenyl)phosphinate; 4-nitrophenyl 4-trifluoromethylphenyl(methyl)phosphinate; 4-nitrophenyl 3-trifluoromethylphenyl(methyl)phosphinate; 4-methylsulfinylphenyl methyl(phenyl)phosphinate.		5. TYPE OF REPORT & PERIOD COVERED  Final June 1981 - September 1981
7. AUTHOR(s)  Leonard J. Sauers, BA, SP5; Freddica R. Pulliam, BS, SSG; John T. Fruin, DVM, PhD, LTC VC;		6. PERFORMING ORG. REPORT NUMBER
9. PERFORMING ORGANIZATION NAME AND ADDRESS  Toxicology Group, Div. of Research Support Letterman Army Institute of Research Presidio of San Francisco, CA 94129		10. PROGRAM ELEMENT PROJECT, TASK AREA & WORK UNIT NUMBERS  Project 3516772A875 WU 304
11. CONTROLLING OFFICE NAME AND ADDRESS  U.S. Army Medical Research and Development Command Fort Detrick Frederick, MD 21701		12. REPORT DATE  September 1981
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		13. NUMBER OF PAGES  38
		15. SECURITY CLASS (of this report)  UNCLASSIFIED
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report)  APPROVED FOR PUBLIC RELEASE: DISTRIBUTION UNLIMITED.		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number)  Mutagenicity; Toxicology, Ames Assay; 4 fluorophenyl methyl(phenyl)phosphinate; 4-nitrophenyl 4-trifluoromethylphenyl(methyl)phosphinate; 4-nitrophenyl 3-trifluoromethyl phenyl(methyl)phosphinate; 4-methylsulfinylphenyl methyl(phenyl)phosphinate.		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number)  The mutagenic potential of 4 fluorophenyl methyl(phenyl)phosphinate (44*); 4-nitrophenyl 4-trifluoromethylphenyl(methyl)phosphinate (86*); 4-nitrophenyl 3-trifluoromethylphenyl(methyl)phosphinate (4*); 4-methylsulfinylphenyl methyl(phenyl)phosphinate (96*) was assessed by using the Ames Salmonella/Mammalian Microsome Mutagenicity Assay. Tester strains TA 98, TA 100, TA 1535, TA 1537 and TA 1538 were exposed to doses ranging from 1 mg/plate to $3.2 \times 10^{-4}$ mg/plate. It was determined that none of the tested substances had mutagenic potential. * Code number for compound.		

## ABSTRACT

The mutagenic potential of 4 fluorophenyl methyl(phenyl)phosphinate (4\*); 4-nitrophenyl 4-trifluoromethylphenyl(methyl)phosphinate (86\*); 4-nitrophenyl 3-trifluoromethylphenyl(methyl)phosphinate (4\*); 4-methylsulfinylphenyl methyl(phenyl)phosphinate (96\*) was assessed by using the Ames Salmonella/Mammalian Microsome Mutagenicity Assay. Tester strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538 were exposed to doses ranging from 1 mg/plate to  $3.2 \times 10^{-4}$  mg/plate. It was determined that none of the tested substances had mutagenic potential.

\* Code number for compound.

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/ _____	
Availability Codes	
Avail and/or	
Dist	Special
A	

PREFACE

AMES ASSAY REPORT:

SUBSTANCE

CODE NO.

4 fluorophenyl methyl(phenyl)phosphinate	44
4-nitrophenyl trifluoromethylphenyl(methyl)phosphinate	86
4-nitrophenyl 3-trifluoromethylphenyl(methyl)phosphinate	4
4-methylsulfinylphenyl methyl(phenyl)phosphinate	96

TESTING FACILITY: Letterman Army Institute of Research  
Presidio of San Francisco, CA 94129

SPONSOR: Biomedical Laboratory, Aberdeen Proving Grounds  
Aberdeen, MD 21005

PROJECT: Toxicity Testing of Phosphinate Compounds - 35162772A875

GLP STUDY NUMBER: 81014

STUDY DIRECTOR: LTC John T. Fruin, D.V.M., PhD.

CO-PRINCIPAL INVESTIGATORS: SSG Freddica R. Pulliam, B.S.  
SP5 Leonard J. Sauers, B.A.

RAW DATA: A copy of the final report, study protocol and retired SOPs  
will be maintained in the LAIR archives. Test substances  
were provided by sponsor. Chemical, analytical, stability,  
purity, etc. data are available from the sponsor.

PURPOSE: To determine the mutagenic potential of the above compounds  
using the Ames Assay. Tester strains TA 98, TA 100, TA  
1535, TA 1537, and TA 1538 were used.

#### **ACKNOWLEDGMENTS**

The authors wish to thank John Dacey and SP4 Larry Mullen,  
BS for their assistance in performing the research and for help  
in preparation of this report.

Signatures of Principal Scientists  
Involved in the Study

We, the undersigned, believe the study, GLP number 81014, described in this report to be scientifically sound and the results and interpretation to be valid. The study was conducted to comply to the best of our ability with the Good Laboratory Practice Regulations outlined by the Food and Drug Administration.

*Freddica R. Pulliam* 8-11-81  
FREDDICA R. PULLIAM, BS Date

SSG  
Co-Investigator

*John T. Fruin* 7-6-81  
JOHN T. FRUIN, DVM, PhD Date  
LTC, VC  
Study Director

*Leonard J. Sauers* July 8,  
LEONARD J. SAUERS, BA Date  
SP5  
Co-Investigator



DEPARTMENT OF THE ARMY  
LETTERMAN ARMY INSTITUTE OF RESEARCH  
PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129

REF ID: A6422  
ATTENTION OF:

SGRD-ULZ-QA

22 July 1981

MEMORANDUM FOR RECORD

SUBJECT: Report of GLP Compliance

I hereby certify that in relation to LAIR GLP study 81014 the following inspections were made:

5 June 1981  
12 June 1981

Routine inspections with no adverse findings are reported quarterly, thus these inspections are also included in the July 1981 report to management.

A handwritten signature in black ink, appearing to read "John C. Johnson".

JOHN C. JOHNSON  
CPT, MS  
Quality Assurance Officer

## TABLE OF CONTENTS

Abstract.....	i
Preface.....	iii
Acknowledgments.....	iv
Signatures of Principal Scientists.....	v
Report of Quality Assurance Unit.....	vi
Table of Contents.....	vii

### BODY OF REPORT

#### INTRODUCTION

Rationale for using the Ames Assay.....	1
Description of Test, Rationale for strain selection.....	1
Description of Strains, History, Methods, and Data.....	2

#### METHODS

Rationale for Dosage Levels and Response Tabulations....	3
Test Format.....	3
Statistical Analysis.....	4
RESULTS AND DISCUSSION.....	4
CONCLUSION.....	5
RECOMMENDATION.....	5
REFERENCES.....	6
APPENDIX (Tables 1 through 6).....	7
DISTRIBUTION LIST.....	28

### Rationale for using the Ames Assay

The Ames Salmonella/Mammalian Microsome Mutagenicity Test is one of a standard bank of tests used by our laboratory for the assessment of the mutagenic potential of a test substance. It is a short-term screening assay for the prediction of potential mutagenic agents in mammals. It is inexpensive when compared to in vivo tests, yet is highly predictive and reliable in its ability to detect mutagenic activity and therefore carcinogenic probability (1). It relies on basic genetic principles and allows for the incorporation of a mammalian microsome enzyme system to increase sensitivity through enzymatically altering the test substance into an active metabolite. It has proven highly effective in assessing human risk (1).

### Description of Test (Rationale for the selection of strains)

The test was developed by Bruce Ames, Ph.D. from the University of California-Berkeley. The test involves the use of several different genetically altered strains of Salmonella typhimurium, each with a specific mutation in the histidine operon (2). The test substance demonstrates mutagenic potential if it is able to revert the mutation in the bacterial histidine operon back to the wild type and thus reestablish prototrophic growth within the test strain. This reversion also can occur spontaneously due to a random mutational event. If, after adding a test substance, the number of revertants is significantly greater than the spontaneous reversion rate, then the test substance physically altered the locus involved in the operon's mutation and is able to induce point mutations and genetic damage (2).

In order to increase the sensitivity of the test system, two other mutations in the Salmonella are used (2). To insure a higher probability of uptake of test substance, the genome for the lipopolysaccharide layer (LP) is mutated and allows larger molecules to enter the bacteria. Each strain has another induced mutation which causes loss of excision repair mechanisms. Since many chemicals are not by themselves mutagenic but have to be activated by an enzymatic process, a mammalian microsome system is incorporated. These microsomal enzymes are obtained from livers of rats induced with Aroclor 1254; the enzymes allow for the expression of the metabolites in the mammalian system. This activated rat liver microsomal enzyme homogenate is termed S-9.

Description of Strains (History of the strains used, methods to monitor the integrity of the organisms, and data pertaining to current and historical controls and spontaneous reversion rates)

The test consists of using five different strains of Salmonella typhimurium that are unable to grow in absence of histidine because of a specific mutation in the histidine operon. This histidine requirement is verified by attempting to grow the tester strains on minimal glucose agar (MGA) plates, both with and without histidine. The dependence on this amino acid is shown when growth occurs only in its presence. The plasmids in strains TA 98 and TA 100 contain an ampicillin resistant R factor. Strains deficient in this plasmid demonstrate a zone of growth inhibition around an ampicillin impregnated disc. The alteration of the LP layer allows uptake by the Salmonella of larger molecules. If a crystal violet impregnated disc is placed onto a plate containing any one of the bacterial strains, a zone of growth inhibition will occur because the LP layer is altered. The absence of excision repair mechanisms can be determined by using ultraviolet (UV) light. These mechanisms function primarily by repairing photodimers between pyrimidine bases; exposure of bacteria to UV light will activate the formation of these dimers and cause cell lethality, since excision of these photodimers can not be made. The genetic mutation resulting in UV sensitivity also induces a dependence by the Salmonella to biotin. Therefore, this vitamin must be added. In order to prove that the bacteria are responsive to the mutation process, positive controls are run with known mutagens. If after exposure to the positive control substance, a larger number of revertants are obtained, then the bacteria are adequately responsive. Sterility controls are performed to determine the presence of contamination. Sterility of the test compound is also confirmed in each first dilution. Verification of the tester strains occurs spontaneously with the running of each assay. The value of the spontaneous reversion rate is obtained using the same inoculum of bacteria that is used in the assay (3).

Strains were obtained directly from Dr. Ames, University of California, Berkeley, propagated and then maintained at -80 C in our laboratory. Before any substance was tested, quality controls were run on the bacterial strains to establish the validity of their special features and also to determine the spontaneous reversion rate (2). Records are maintained of all the data, to determine if deviations from the set trends have occurred.

We compared the spontaneous reversion values with our own historical values and those cited by Ames et al (2). Our conclusions are based on the spontaneous reversion rate compared to the experimentally induced rate of mutation. When operating effectively, these strains detect substances that cause base pair

mutations (TA 1535, TA 100) and frameshift mutations (TA 1537, TA 1538 and TA 98) (2).

### METHODS (3)

#### Rationale for Dosage Levels and Dose Response Tabulations

To insure readable and reliable results, a sublethal concentration of the test substance had to be determined. This toxicity level was found by using MGA plates, various concentrations of the substance, and approximately  $10^8$  cells of TA 100 per plate, unless otherwise specified. Top agar containing trace amounts of histidine and biotin were placed on MGA plates. TA 100 is used because it is the most sensitive strain. Strain verification was confirmed on the bacteria, along with a determination of the spontaneous reversion rate. After incubation, the growth was observed on the plates. (The auxotrophic Salmonella will replicate a few times and potentially express a mutation. When the histidine and biotin supplies are exhausted, only those bacteria that reverted to the prototrophic phenotype will continue to reproduce and form macro-colonies; the remainder of the bacteria comprises the background lawn. The minimum toxic level is defined as the lowest serial dilution at which decreased macrocolony formation, below that of the spontaneous revertant rate, and an observable reduction in the density of the background lawn occurs.) A maximum dose of 1 mg/plate is used when no toxicity is observed. The densities were recorded as normal slight, and no growth.

#### Test Format

After we validated our bacterial strains and determined the optimal dosage of the test substance, we began the Ames Assay. In the actual experiment, 0.1ml of the particular strain of Salmonella ( $10^8$  cells) and the specific dilutions of the test substance were added to 2 ml of molten top agar, which contained trace amounts of histidine and biotin. Since survival is better from cultures which have just passed the log phase, the Salmonella strains were used 16 hours (maximum) after initial inoculation into nutrient broth. The dose of the test substance spanned more than a 1000-fold, decreasing from the minimum toxic level by a dilution factor of 5. All the substances were tested with and without S-9 microsome fraction. The S-9 mixture which was previously titered at an optimal strength was added to the molten top agar. After all the ingredients were added, the top agar was vortexed, then overlayed on minimum glucose agar plates. These plates contained 2% glucose and Vogel Bonner "E" Concentrate (4). The water used in this medium and all reagents came from a polymetric system. Plates were incubated, upside down in the dark at 37 C for 48 hours. Plates were prepared in triplicate and

the average revertant counts were recorded. The corresponding number of revertants obtained was compared to the number of spontaneous revertants; the conclusions were recorded statistically. A correlated dose response is considered necessary to declare a substance as a mutagen. Commoner (5), in his report, "Reliability of Bacterial Mutagenesis Techniques to Distinguish Carcinogenic and Non-Carcinogenic Chemical," and McCann et al (1) in their paper, "Detection of Carcinogens as Mutagen: Assay of over 300 Chemicals," have concurred on the test's ability to detect mutagenic potential.

#### Statistical Analysis

Quantitative evaluation was ascertained by two independent methods. Ames et al (2) assumed that a compound which caused twice the spontaneous reversion rate is mutagenic. Commoner (5), developed the MUTAR Ratio, which is stated in the following equation:

$$\text{MUTAR} = (E - C)/C_{AV}$$

Here, C is the number of spontaneous revertant colonies on control plates obtained on the same day and with the same treatment and strains. E is the number of revertants in response to the compound;  $C_{AV}$  is the number of spontaneous revertants on control plates calculated from historical records. The explanation of the results of this equation can be determined by the method of Commoner (5). This variation determines the probability of correctly classifying substances as carcinogens on the basis of their mutagenic activity. The E values were recorded by strain, with and without S-9. Values for C and  $C_{AV}$  were recorded separately.

We used the formula and logged all values for our permanent records.

#### RESULTS AND DISCUSSION

Throughout this report, each of the test substances will be referred to by the respective code number:

<u>Substance</u>	<u>Code No.</u>
4 fluorophenyl methyl(phenyl)phosphinate	44
4-nitrophenyl 4-trifluoromethylphenyl(methyl)phosphinate	86
4-nitrophenyl 3-trifluoromethylphenyl(methyl)phosphinate	4
4-methylsulfinylphenyl methyl(phenyl)phosphinate	96

On 5 June 1981, the Toxicity Level Determination was performed on the 4 test chemicals. All sterility, positive, and negative controls for this experiment were normal (Table 1). At the highest dose used, 1.0 mg/plate, no toxicity was observed (Tables 2A-2D).

On 12 June 1981, the Ames Assay was performed using the 4 test substances. For this experiment, all sterility and strain verification controls were normal (Table 3). Expected responses were observed for all negative and positive controls except for the response of TA 1537 and TA 1538 to dimethyl benzantracene (DMBA) (Table 4).

For all chemicals tested, no evidence of mutagenic potential was observed (Tables 5A-5D).

The MUTAR values listed in Tables 6A-6D, were within the normal limits.

#### CONCLUSION

By the Ames Assay, test compounds, 86, 44, 4 and 96 are not mutagenic at the levels tested.

#### RECOMMENDATION

We recommend that organophosphinate compounds 86, 44, 4 and 96 be tested by using other toxicological testing systems if efficacy tests show these chemicals to be promising antidotes.

REFERENCES

1. McCANN, J., E. CHOI, E. YAMASAKI, and B. N. AMES. Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals. Proc Nat Acad Sci, USA 72:5135-5139, 1975
2. AMES, B. N., J. McCANN and E. YAMASAKI. Methods for detection carcinogens and mutagens with Salmonella/mammalian microsome mutagenicity test. Mutation Res 31: 347-364, 1975
3. LAIR SOP OP-STX-1, Ames Salmonella/mammalian microsome mutagenicity test, 1 March 1981
4. VOGEL, H. J. and D. M. BONNER. Acetylornithinase of *E. coli*: Partial purification and some properties. J Biol Chem 218: 97-106, 1956
5. COMMONER, B. Reliability of the bacterial mutagenesis techniques to distinguish carcinogenic and non-carcinogenic chemicals. EPA 600/1 76-022, 1976

## LIST OF TABLES

	Code	Page
Table 1 Strain Verification for Toxicity Level Determination		9
Table 2A Toxicity Level Determination	86	10
Table 2B Toxicity Level Determination	44	11
Table 2C Toxicity Level Determination	4	12
Table 2D Toxicity Level Determination	96	13
Table 3 Strain Verification and Sterility Controls		14
Table 4 Positive and Negative Controls		15
Table 5A Ames Assay Worksheet	86	16
Table 5B Ames Assay Worksheet	44	18
Table 5C Ames Assay Worksheet	4	20
Table 5D Ames Assay Worksheet	96	22
Table 6A Mutagenic Activity Ratio	86	24
Table 6B Mutagenic Activity Ratio	44	25
Table 6C Mutagenic Activity Ratio	4	26
Table 6D Mutagenic Activity Ratio	96	27

## APPENDIX

TABLE 1  
STRAIN VERIFICATION FOR TOXICITY LEVEL DETERMINATION  
Salmonella/Microsome Assay

Strain No.	Histidine Requirements	Ampicillin Resistance	uvr-B Deletion	rfa Crystal Violet	Sterility Control	Response (a)
TA 100	NG	G	NG	14.15 mm	NG	+
TA 1537	NA	NG	NA	NA	NG	+
WT	G	NA	G	NA	NA	+
Diluent	NA	NA	NA	NA	NG	+
Positive Control - MNNG - Average - 1612						
Test Compound (s)						
(a) 44	NA	NA	NA	NA	NG	+
(b) 86	NA	NA	NA	NA	NG	+
(c) 4	NA	NA	NA	NA	NG	+
(d) 96	NA	NA	NA	NA	NG	+
(e) NA	NA	NA	NA	NA	NA	NA

G = Growth; NG = No Growth; NT = Not Tested; NA = Not Applicable;  
 WT = Wild Type; (a) + = Expected Response; - = Unexpected Response

Spontaneous Revertants

Strain	Time				Average
TA 100	Beginning	152	116	139	
TA 100	End	159	157	142	144

Test Inculated By: Sauers, Pulliam, Dacey, Mullen Date 3 June 1981

Test Read By: Sauers, Pulliam Date 5 June 1981

TABLE 2A

**TOXICITY LEVEL DETERMINATION  
Salmonella/Microsome Assay**

Substance assayed: (1) Code #86 (2) \_\_\_\_\_

(3) \_\_\_\_\_ (4) \_\_\_\_\_ (5) \_\_\_\_\_

Date: 3 June 1981 Performed by: Sauers, Pulliam, Dacey, Mullen

Substance dissolved in: (1) DMSO (2) \_\_\_\_\_ (3) \_\_\_\_\_

(4) \_\_\_\_\_ (5) \_\_\_\_\_

Visual estimation of background lawn on  
Nutrient Agar Plates: NG = no growth  
ST = slight growth  
NL = normal growth

TABLE 2B

**TOXICITY LEVEL DETERMINATION  
Salmonella/Microsome Assay**

Substance assayed: (1) Code #44 (2) \_\_\_\_\_  
(3) \_\_\_\_\_ (4) \_\_\_\_\_ (5) \_\_\_\_\_

Date: 3 June 1981 Performed by: Sauers, Pulliam, Dacey, Mullen

Substance dissolved in: (1) DMSO (2) \_\_\_\_\_ (3) \_\_\_\_\_  
(4) \_\_\_\_\_ (5) \_\_\_\_\_

Visual estimation of background lawn on  
Nutrient Agar Plates: NG = no growth  
ST = slight growth  
NL = normal growth

TA 100  
Revertant Plate Count

TABLE 2C  
TOXICITY LEVEL DETERMINATION  
*Salmonella*/Microsome Assay

Substance assayed: (1) Code #4 (2) \_\_\_\_\_  
(3) \_\_\_\_\_ (4) \_\_\_\_\_ (5) \_\_\_\_\_

Date: 3 June 1981 Performed by: Sauers, Pulliam, Dacey, Mullen

Substance dissolved in: (1) DMSO (2) \_\_\_\_\_ (3) \_\_\_\_\_

(4) \_\_\_\_\_ (5) \_\_\_\_\_ Visual estimation of background label

(4) \_\_\_\_\_ (5) \_\_\_\_\_ Visual estimation of background lawn on Nutrient Agar Plates: NG = no growth ST = slight growth NL = normal growth

TABLE 2D

**TOXICITY LEVEL DETERMINATION  
Salmonella/Microsome Assay**

Substance assayed: (1) Code #96 (2) \_\_\_\_\_  
(3) \_\_\_\_\_ (4) \_\_\_\_\_ (5) \_\_\_\_\_

Date: 3 June 1981 Performed by: Sauers, Pulliam, Dacey, Mullen

Substance dissolved in: (1) DMSO (2) \_\_\_\_\_ (3) \_\_\_\_\_

(4) \_\_\_\_\_ (5) \_\_\_\_\_

Visual estimation of background lawn on  
Nutrient Agar Plates: NG = no growth  
ST = slight growth  
NL = normal growth

TA 100  
Revertant Plate Count

TABLE 3

STRAIN VERIFICATION CONTROL

Strains	Histidine Requirement	Ampicillin Resistance	UV	Sensitivity to Crystal Violet		Sterility Control	Response (1)
				NG	G		
98	NG	NG	NG	NG	NG	NG	+
100	NG	NG	NG	NG	NG	NG	+
1535	NG	NA	NA	NG	NG	NG	+
1537	NG	21.26 mm	NG	14.11 mm	NG	NG	+
1538	NG	NA	NG	15.34 mm	NG	NG	+
WT	G	NA	G	15.39 mm	NG	NA	+

STERILITY CONTROL

His-Bio Mix	Initial: <u>NG</u>	End: <u>NG</u>	Diluent: <u>NG</u>
Top Agar	Initial: <u>NG</u>	End: <u>NG</u>	MGA Plate: <u>NG</u>
S-9 Mix	Initial: <u>NG</u>	End: <u>NG</u>	Nutrient Broth: <u>NG</u>
Test Compound	(a) <u>96-NG</u>	(b) <u>4-NG</u>	(c) <u>4A-NG</u>
			(d) <u>86-NG</u> (e) <u>NA</u> (f) <u>NA</u>

G = Growth NC = No Growth NT = Not Tested NA = Not Applicable WT = Wild Type

Study Number: 81014 By: Sauers, Pulliam. (1) + = expected responseDate: 12 June 1981 Dacey, Mullen - = unexpected response

**TABLE 4**  
SPONTANEOUS REVERTANT RATE AND POSITIVE CONTROL REVERTANT RATE

Compd.	Amount of Compd. Added	S-9		Strain Number		1538 (256, 580, 487) (41)	
		Added	98	100	1535	1537	
AF	2 ug/plate	yes	(329, 558, 235) (374)	(369, 168, 315) (284)			
BF	2 ug/plate	yes	(62, 66, 59) (62)	(234, 302, 396) (311)	(12, 69, 52) (44)	(97, 115, 72) (95)	
DMBA	20 ug/plate	yes	(62, 71, 66) (66)	(251, 202, 264) (239)	(16, 15, 15) (15)	(38, 41, 18) (32)	
MNNG	2 ug/plate	no		(912, 1154, 760) (942)			
	20 ug/plate	no			(1112, 216, 366) (231)		

Strain Performance

Spontaneous Revertants

before	yes	(37, 19, 19) (37, 37, 28)	(89, 80, 123) (141, 135, 118)	(14, 8, 9) (7, 9, 12)	(5, 7, 7) (12, 10, 6)	(15, 12, 9) (26, 23, 29)
after		(30)	(114)	(10)	(8)	(19)
before	no	(26, 15, 19) (20, 26, 24)	(80, 87, 93) (102, 99, 106)	(25, 12, 11) (17, 20, 17)	(9, 7, 6) (7, 4, 8)	(5, 18, 17) (21, 26, 22)
after		(22)	(94)	(17)	(7)	(18)

Study Number: 81014

Date: 12 Jun 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5A

		<u>NUMBER OF REVERTANTS/PLATE</u>			<u>Strain Number</u>	
<u>Concd.</u>	<u>Amount of Compd. Added</u>	<u>S-a Added</u>	<u>100</u>	<u>1535</u>	<u>1537</u>	<u>1538</u>
Code #36 1 mg/plate	no	(10,17,15) (14)	(95,83,108) (95)	(15,13,15) (14)	(8,4,5) (6)	(9,13,12) (11)
	yes	(20,35,24) (26)	(126,98,112) (112)	(9,4,5) (6)	(8,8,4) (7)	(21,14,23) (19)
Code #86 0.2 mg/plate	no	(14,18,20) (17)	(102,97,80) (93)	(20,19,12) (17)	(5,4,6) (5)	(4,10,7) (7)
	yes	(19,26,29) (25)	(110,93,102) (102)	(8,10,9) (9)	(6,5,9) (7)	(31,27,30) (29)
Code #86 0.04 mg/plate	no	(17,12,12) (14)	(75,90,107) (91)	(7,19,11) (12)	(7,2,7) (5)	(11,12,11) (11)
	yes	(35,30,30) (32)	(137,120,104) (120)	(9,10,12) (10)	(8,10,6) (8)	(32,22,37) (30)

-continued

Study Number: 81014 Date: 19 Jun 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5A, concluded

		<u>NUMBER OF REVERTANTS/PLATE</u>			<u>Strain</u>	<u>Number</u>	
<u>Compd.</u>	<u>Amount of Compd.</u>	<u>S-9 Added</u>	<u>98</u>	<u>100</u>	<u>1535</u>	<u>1537</u>	<u>1538</u>
Code #86	0.008 mg/plate	no	(17,19,14) (17)	(94,30,113) (96)	(17,7,10) (11)	(7,10,8) (8)	(14,17,7) (13)
		yes	(29,23,35) (29)	(116,140,93) (116)	(10,9,10) (10)	(9,7,4) (7)	(28,30,24) (27)
Code #86	0.0016 mg/plate	no	(15,18,15) (16)	(95,104,107) (102)	(10,14,12) (12)	(11,10,6) (9)	(5,10,14) (10)
		yes	(26,18,27) (24)	(136,116,117) (123)	(14,12,20) (15)	(12,10,12) (11)	(12,18,36) (22)
Code #86	0.00032 mg/plate	no	(12,19,12) (14)	(95,108,113) (105)	(19,18,15) (17)	(6,5,8) (6)	(18,10,13) (14)
		yes	(24,32,28) (28)	(128,120,92) (113)	(11,11,15) (12)	(7,5,6) (6)	(23,17,26) (22)

Study Number: 81014Date: 19 Jun 81By: Sauers, Pulliam, Dacey, Mullen

TABLE 5B

		NUMBER OF REVERTANTS/PLATE					
Compd.	Amount of Compd. Added	S-9 Added	98	100	strain 15J5	Number 1537	1538
Code #44 1 mg/plate	no	(15,23,15) (13)	(70,53,54) (59)	(3,5,4) (4)	(2,2,3) (2)	(8,7,7) (7)	
	yes	(40,17,23) (27)	(85,80,80) (82)	(10,6,5) (7)	(12,8,4) (8)	(4,5,5) (4)	
Code #44 0.2 mg/plate	no	(31,16,12) (20)	(83,102,91) (92)	(20,15,14) (16)	(5,3,8) (5)	(13,12,4) (10)	
	yes	(29,25,32) (29)	(121,111,113) (115)	(6,9,9) (8)	(10,9,4) (8)	(22,21,22) (22)	
.							
Code #44 0.04	no	(25,14,20) (20)	(92,95,69) (85)	(18,19,20) (19)	(4,7,3) (5)	(12,11,12) (12)	
	yes	(21,21,30) (24)	(108,117,97) (107)	(12,8,12) (11)	(4,6,5) (5)	(7,25,29) (20)	

- continued

Study Number: 81014

Date: 19 Jun 81

By: Sauers, Pulliam, Dacey, Mullen

TABLE 5B, concluded

		<u>NUMBER OF REVERTANTS/PLATE</u>				
Compd.	Amount of Compd. Added	S-9 Added	98	100	<u>Strain Number</u>	
Code #44 0.0008 mg/plate	no	(18,20,23) (20)	(72,100,96) (39)	(15,23,20) (19)	(7,6,6) (6)	(12,9,9) (10)
	yes	(26,34,24) (28)	(133,112,109) (118)	(11,14,11) (12)	(5,8,7) (7)	(27,17,15) (20)
Code #44 0.0016 mg/plate	no	(13,26,12) (17)	(93,86,70) (83)	(11,10,8) (10)	(5,3,6) (5)	(6,12,14) (11)
	yes	(23,29,21) (24)	(95,103,99) (99)	(12,13,8) (11)	(5,15,5) (8)	(32,17,20) (23)
Code #44 0.00032 mg/plate	no	(29,11,13) (18)	(96,96,105) (100)	(15,17,15) (16)	(2,6,3) (4)	(7,10,12) (10)
	yes	(31,26,24) (27)	(119,103,103) (108)	(20,13,11) (15)	(6,4,11) (7)	(12,28,15) (18)

Study Number: 31014 Date: 19 June 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5C

Compd.	Amount of Compd. Added	NUMBER OF REVERTANTS/FLAYE			<u>Strain Number</u> <u>1535</u>	<u>1537</u> <u>1538</u>
		S-q Added	98	100		
Code #4	1 mg/plate	yes	(21, (20)	(127, (141)164,133)	(9, (8)8,7)	(9, (8)8,7)
		no	(13, (14)15,15)	(125, (115)127,92)	(20, (16)14,15)(4, (6)9,6)	(13, (19)17,28)
Code #4	0.2 mg/plate	yes	(17,32,23) (24)	(115, (113)113,110)	(9, (12)17,9)	(5, (7)9,8)
		no	(17, (15)17,12)	(74, (76)72,82)	(15, (17)18,18)(10, (7)3,8)	(18, (15)15,12)
Code #4	0.04 mg/plate	yes	(25,23,28) (25)	(140, (120)104,116)	(9, (11)13,12)	(7, (6)7,5)
		no	(17, (16)20,12)	(75, (83)85,90)	(12, (11)8,14)	(4, (6)6,8)

-continued

Study Number: 81014 Date: 19 June 81 By: Sauers, Pulliam, Dacey, Mullen

TABLE 5C, concluded

Compd.	Amount of Compd. Added	NUMBER OF REVERTANTS/PLATE			Strain Number 1535	Strain Number 1537	1538
		S-9	98	100			
Code #4	0.008 mg/plate	no	(18, 15, 17) (16)	(63, 77, 107) (82)	(20, 31, 14) (22)	(10, 9, 6) (8)	(24, 17, 36) (26)
	yes	(27, 28, 23) (26)	(139, 148, 129) (139)	(8, 8, 12) (9)	(6, 5, 9) (7)	(26, 15, 38) (26)	
21	Code #4	0.0016 mg/plate	no	(16, 16, 21) (18)	(95, 105, 96) (99)	(17, 15, 18) (17)	(6, 6, 4) (5)
	yes	(39, 40, 28) (36)	(160, 154, 122) (145)	(5, 12, 9) (9)	(5, 6, 8) (6)	(23, 21, 34) (26)	
Code #4	0.00032 mg/plate	no	(22, 12, 12) (15)	(100, 85, 114) (100)	(8, 18, 16) (14)	(5, 4, cont) (4)	(12, 7, 8) (9)
	yes	(27, 26, 29) (27)	(130, 96, 126) (117)	(8, 7, 6) (6)	(9, 2, 5) (5)	(17, 30, 15) (21)	

TABLE 5D

## NUMBER OF REVERTANTS/PLATE

Compd.	Amount of Compd. Added	S-9 Added	98	100	Strain $\frac{1535}{1537}$	Number 1538
Code #96 1 mg/plate	no	(19,17,12) (16)	(137,95,95) (109)	(15,17,15) (16)	(4,5,7) (5)	(5,9,5) (6)
	yes	(35,20,24) (26)	(121,145,105) (124)	(9,12,11) (11)	(8,6,7) (6)	(33,20,11) (21)
Code #96 0.2 mg/plate	no	(18,13,14) (15)	(85,96,77) (86)	(14,9,11) (11)	(4,8,5) (6)	(6,4,13) (8)
	yes	(35,27,27) (30)	(124,130,118) (124)	(5,11,11) (9)	(4,6,7) (6)	(16,9,15) (13)
Code #96 0.04 mg/plate	no	(12,15,27) (18)	(68,98,104) (90)	(18,15,18) (17)	(6,6,5) (6)	(3,12,13) (11)
	yes	(35,35,34) (35)	(146,99,120) (122)	(12,8,8) (9)	(7,6,7) (7)	(18,9,20) (16)

-continued

Study Number: 81014Date: 19 Jun 81By: Sauers, Pulliam, Dacey, Mullen

TABLE 5D , concluded

Compd.	Amount of Compd. Added	NUMBER OF REVERTANTS/PLATE			Strain <u>1535</u>	Strain <u>1537</u>	Strain <u>1538</u>
		S-9 Added	98	100			
Code #96 0.008 mg/plate	no	(13,18,11)	(96,95,10)	(13,15,14)	(5,10,4)	(17,12,9)	
		(14)	(67)	(14)	(6)	(13)	
yes	(25,29,24)	(113,113,117)	(11,8,11)	(4,3,2)	(23,26,18)		
	(26)	(114)	(10)	(3)	(22)		
Code #96 0.0016 mg/plate	no	(12,17,14)	(85,93,79)	(18,9,18)	(3,4,6)	(10,10,17)	
		(14)	(86)	(15)	(4)	(12)	
yes	(26,29,28)	(118,124,110)	(6,10,10)	(4,7,7)	(17,21,23)		
	(28)	(117)	(9)	(6)	(20)		
Code #96 0.00032 mg/plate	no	(13,19,19)	(90,92,108)	(17,12,9)	(6,7,9)	(17,12,13)	
		(17)	(97)	(13)	(7)	(14)	
yes	(26,30,26)	(117,146,108)	(11,7,6)	(4,7,6)	(26,23,20)		
	(27)	(124)	(8)	(6)	(23)		

Study Number: 81014 Date: 19 Jun 81 By: Sauers, Pulliam, Dacev, Mullen

TABLE 6A  
MUTAGENIC ACTIVITY RATIO

Substance Assayed: Code #86 Dissolved in: DMSO

Study Number: 81014 Date: 23 July 1981 By: Sauers

Concentration	Strain	MUTAR (act)	MUTAR	Concentration	Strain	MUTAR (act)	MUTAR
1.0 mg/plate	TA 98	*	*	0.008 mg/pl.	TA 1535	*	*
0.2 mg/plate	TA 98	*	*	0.0016 mg/pl.	TA 1535	0.45	*
0.04 mg/plate	TA 98	0.08	*	0.00032 mg/pl.	TA 1535	0.18	*
0.008 mg/plate	TA 98	*	*				
0.0016 mg/pl.	TA 98	*	*	1.0 mg/plate	TA 1537	*	*
0.00032 mg/pl.	TA 98	*	*	0.2 mg/plate	TA 1537	*	*
				0.04 mg/plate	TA 1537	*	*
1.0 mg/plate	TA 100	*	0.01	0.008 mg/pl.	TA 1537	*	0.15
0.2 mg/plate	TA 100	*	*	0.0016 mg/pl.	TA 1537	0.46	0.31
0.04 mg/plate	TA 100	0.06	*	0.00032 mg/pl.	TA 1537	*	*
0.008 mg/plate	TA 100	0.02	0.02				
0.0016 mg/pl.	TA 100	0.08	0.08	1.0 mg/plate	TA 1538	*	*
0.00032 mg/pl.	TA 100	*	0.12	0.2 mg/plate	TA 1538	0.53	*
				0.04 mg/plat.	TA 1538	0.59	*
1.0 mg/plate	TA 1535	*	*	0.008 mg/plate	TA 1538	0.43	*
0.2 mg/plate	TA 1535	*	*	0.0016 mg/pl.	TA 1538	0.16	*
0.04 mg/plate	TA 1535	*	*	0.00032 mg/pl.	TA 1538	0.16	*

(act): S-9 fraction was added

\* : calculated value resulted in a negative MUTAR or zero MUTAR

TABLE 6B  
MUTAGENIC ACTIVITY RATIO

Substance Assayed: Code # 44 Dissolved in: DMSO  
Study Number: 81014 Date: 23 July 1981 By: Sauers

Concentration	Strain	MUTAR (act)	MUTAR	Concentration	Strain	MUTAR (act)	MUTAR
1.0 mg/plate	TA 98	*	*	0.008 mg/plate	TA 1535	0.18	0.13
0.2 mg/plate	TA 98	*	*	0.0016 mg/pl.	TA 1535	0.09	*
0.04 mg/plate	TA 98	*	*	0.00032 mg/pl.	TA 1535	0.45	*
0.008 mg/plate	TA 98	*	*				
0.0016 mg/pl.	TA 98	*	*	1.0 mg/plate	TA 1537	*	*
0.00032 mg/pl.	TA 98	*	*	0.2 mg/plate	TA 1537	*	*
				0.04 mg/plate	TA 1537	*	*
1.0 mg/plate	TA 100	*	*	0.008 mg/plate	TA 1537	*	*
0.2 mg/plate	TA 100	0.01	*	0.0016 mg/pl.	TA 1537	*	*
0.04 mg/plate	TA 100	*	*	0.00032 mg/pl.	TA 1537	*	*
0.008 mg/plate	TA 100	0.04	*				
0.0016 mg/pl.	TA 100	*	*	1.0 mg/plate	TA 1538	*	*
0.00032 mg/pl.	TA 100	*	0.06	0.2 mg/plate	TA 1538	0.16	*
				0.04 mg/plate	TA 1538	0.05	*
1.0 mg/plate	TA 1535	*	*	0.008 mg/plate	TA 1538	0.05	*
0.2 mg/plate	TA 1535	*	*	0.0016 mg/plate	TA 1538	0.21	*
0.04 mg/plate	TA 1535	0.09	0.13	0.00032 mg/pl.	TA 1538	*	*

(act): S-9 fraction was added

\* : calculated value resulted in a negative MUTAR or zero MUTAR

TABLE 6C  
MUTAGENIC ACTIVITY RATIO

Substance Assayed: Code #4 Dissolved in: DMSO

Study Number: 81014 Date: 23 July 1981 By: Sauers

Concentration	Strain	MUTAR (act)	MUTAR	Concentration	Strain	MUTAR (act)	MUTAR
1.0 mg/plate	TA 98	*	*	0.008 mg/plate	TA 1535	*	0.32
0.2 mg/plate	TA 98	*	*	0.0016 mg/pl.	TA 1535	*	*
0.04 mg/plate	TA 98	*	*	0.00032 mg/pl.	TA 1535	*	*
0.008 mg/plate	TA 98	*	*				
0.0016 mg/pl.	TA 98	0.24	*	1.0 mg/plate	TA 1537	*	*
0.00032 mg/pl.	TA 98	*	*	0.2 mg/plate	TA 1537	*	*
				0.04 mg/plate	TA 1537	*	*
1.0 mg/plate	TA 100	0.25	0.12	0.008 mg/plate	TA 1537	*	0.15
0.2 mg/plate	TA 100	*	*	0.0016 mg/pl.	TA 1537	*	*
0.04 mg/plate	TA 100	0.06	*	0.00032 mg/pl.	TA 1537	*	*
0.008 mg/plate	TA 100	0.23	*				
0.0016 mg/pl.	TA 100	0.29	0.05	1.0 mg/plate	TA 1538	*	*
0.00032 mg/pl.	TA 100	0.03	0.06	0.2 mg/plate	TA 1538	*	*
				0.04 mg/plate	TA 1538	*	*
1.0 mg/plate	TA 1535	*	*	0.008 mg/plate	TA 1538	0.37	0.42
0.2 mg/plate	TA 1535	0.18	*	0.0016 mg/pl.	TA 1538	0.37	*
0.04 mg/plate	TA 1535	0.09	*	0.00032 mg/pl.	TA 1538	0.11	*

(act): S-9 fraction was added

\* : calculated value resulted in a negative MUTAR or zero MUTAR

TABLE 6D  
MUTAGENIC ACTIVITY RATIO

Substance Assayed: Code #96 Dissolved in: DMSO  
Study Number: 81014 Date: 23 July 1981 By: Sauers

Concentration	Strain	MUTAR (act)	MUTAR	Concentration	Strain	MUTAR (act)	MUTAR
1.0 mg/plate	TA 98	*	*	0.008 mg/plate	TA 1535	*	*
0.2 mg/plate	TA 98	*	*	0.0016 mg/pl.	TA 1535	*	*
0.04 mg/plate	TA 98	0.2	*	0.00032 mg/pl.	TA 1535	*	*
0.008 mg/plate	TA 98	*	*				
0.0016 mg/pl.	TA 98	*	*	1.0 mg/plate	TA 1537	*	*
0.00032 mg/pl.	TA 98	*	*	0.2 mg/plate	TA 1537	*	*
				0.04 mg/plate	TA 1537	*	*
1.0 mg/plate	TA 100	0.09	0.16	0.008 mg/plate	TA 1537	*	*
0.2 mg/plate	TA 100	0.09	*	0.0016 mg/pl.	TA 1537	*	*
0.04 mg/plate	TA 100	0.07	*	0.00032 mg/pl.	TA 1537	*	*
0.008 mg/plate	TA 100	*	*				
0.0016 mg/pl.	TA 100	0.03	*	1.0 mg/plate	TA 1538	0.11	*
0.00032 mg/pl.	TA 100	0.09	0.03	0.2 mg/plate	TA 1538	*	*
				0.04 mg/plate	TA 1538	*	*
1.0 mg/plate	TA 1535	0.09	*	0.008 mg/plate	TA 1538	0.16	*
0.2 mg/plate	TA 1535	*	*	0.0016 mg/pl.	TA 1538	0.05	*
0.04 mg/plate	TA 1535	*	*	0.00032 mg/pl.	TA 1538	0.21	*

(act): S-9 fraction was added

\* : calculated value resulted in a negative MUTAR or zero MUTAR

### **OFFICIAL DISTRIBUTION LIST**

<b>Commander</b> <b>US Army Medical Research and Development Command</b> <b>ATTN: SGRD-SI/ Mrs. Madigan</b> <b>Fort Detrick, Frederick MD 21701</b>	<b>Director</b> <b>Walter Reed Army Institute of Research</b> <b>Washington DC 20012</b>
<b>Defense Technical Information Center</b> <b>ATTN: DTIC-DDA</b> <b>Cameron Station</b> <b>Alexandria VA 22314</b>	<b>(12 copies)</b>
<b>Director of Defense Research and Engineering</b> <b>ATTN: Assistant Director, Environmental and</b> <b>Life Sciences</b> <b>Washington DC 20301</b>	<b>Commander</b> <b>US Army Medical Research Institute of Infectious</b> <b>Diseases</b> <b>Fort Detrick, Frederick MD 21701</b>
<b>The Surgeon General</b> <b>ATTN: DASG-TLO</b> <b>Washington DC 20314</b>	<b>Commander</b> <b>US Army Research Institute of Environmental</b> <b>Medicine</b> <b>Natick MA 01760</b>
<b>HQ DA (DASG-ZXA)</b> <b>WASH DC 20310</b>	<b>Commander</b> <b>US Army Institute of Surgical Research</b> <b>Brooke Army Medical Center</b> <b>Fort Sam Houston TX 78234</b>
<b>Superintendent</b> <b>Academy of Health Sciences</b> <b>ATTN: AHS-COM</b> <b>Fort Sam Houston TX 78234</b>	<b>Commander</b> <b>US Army Institute of Dental Research</b> <b>Washington DC 20012</b>
<b>Assistant Dean</b> <b>Institute and Research Support</b> <b>Uniformed Services University of Health Sciences</b> <b>9917 Arlington Road</b> <b>Bethesda MD 20014</b>	<b>Commander</b> <b>US Army Medical Bioengineering</b> <b>Research and Development Laboratory</b> <b>Fort Detrick, Frederick MD 21701</b>
<b>Commander</b> <b>US Army Environmental Hygiene Agency</b> <b>Aberdeen Proving Ground MD 21070</b>	<b>Commander</b> <b>US Army Aeromedical Research Laboratory</b> <b>Fort Rucker AL 36362</b>
<b>US Army Research Office</b> <b>ATTN: Chemical and Biological Sciences Division</b> <b>P.O. Box 1221</b> <b>Research Triangle Park NC 27709</b>	<b>Commander</b> <b>US Army Biomedical Laboratory</b> <b>Aberdeen Proving Ground</b> <b>Edgewood Arsenal MD 21010</b>
<b>Biological Sciences Division</b> <b>Office of Naval Research</b> <b>Arlington VA 22217</b>	<b>Commander</b> <b>Naval Medical Research Institute</b> <b>National Naval Medical Center</b> <b>Bethesda MD 20014</b>
<b>Director of Life Sciences</b> <b>USAF Office of Scientific Research (AFSC)</b> <b>Bolling AFB</b> <b>Washington DC 20332</b>	<b>Commander</b> <b>USAF School of Aerospace Medicine</b> <b>Aerospace Medical Division</b> <b>Brooks Air Force Base TX 78235</b>

